Last reviewed · How we verify
AND017
AND017 is a small molecule that targets the SGLT2 receptor.
AND017 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | AND017 |
|---|---|
| Sponsor | Kind Pharmaceuticals LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
AND017 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital yeast infections
- Increased risk of hypotension
Key clinical trials
- A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia (PHASE3)
- A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PHASE3)
- A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy (PHASE2)
- A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia (PHASE2)
- A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome (PHASE2)
- A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy (PHASE2)
- A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis (PHASE2)
- A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AND017 CI brief — competitive landscape report
- AND017 updates RSS · CI watch RSS
- Kind Pharmaceuticals LLC portfolio CI